The IL-3Rα-Targeted Drug SL-401 Selectively Kills Blastic Plasmacytoid Dendritic Cell Neoplasm Cells. ASH 2011.
The IL-3Rα-Targeted Drug SL-401 Selectively Kills Blastic Plasmacytoid Dendritic Cell Neoplasm Cells. ASH 2011. Abstract | Poster
Hodgkin's Lymphoma Cell Lines Have Up-Regulated IL-3 Receptor α (IL-3Rα) Expression and Are Sensitive to SL-401, an IL-3Rα-Targeted Drug
Hodgkin’s Lymphoma Cell Lines Have Up-regulated IL-3 Receptor α (IL-3Rα) Expression and are Sensitive to SL-401, an IL-3Rα-Targeted Drug. ASH 2011. Abstract | Poster
Phase I/II Vaccine Study Targeting Novel HLA-A2-Restricted CTL Epitopes in Combination With Poly-ICLC in Patients With Recurrent Malignant Glioma
Phase I/II vaccine study targeting novel HLA-A2-restricted CTL epitopes in combination with poly-ICLC in patients with recurrent malignant glioma. ASCO 2011. Abstract